作者：
Maxwell,Pistilli [1]
;
Sapna S,Gangaputra [2]
;
Siddharth S,Pujari [3]
;
Douglas A,Jabs [4]
;
Grace A,Levy-Clarke [5]
;
Robert B,Nussenblatt [6]
;
James T,Rosenbaum [7]
;
H Nida,Sen [6]
;
Eric B,Suhler [8]
;
Jennifer E,Thorne [9]
;
Nirali P,Bhatt [6]
;
C Stephen,Foster [8]
;
Hosne,Begum [9]
;
Tonetta D,Fitzgerald [10]
;
Kurt A,Dreger [4]
;
John H,Kempen [5]
作者单位：
and the Systemic Immunosuppressive Therapy for Eye Diseases (SITE) Research Group** Department of Ophthalmology, The University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA.
[1]
Department of Ophthalmology and Vision Sciences, Vanderbilt Eye Institute, Nashville, Tennessee, USA.
[2]
Om Eye Care Hospital, Belgaum, India.
[3]
Department of Epidemiology, The Johns Hopkins University Bloomberg School of Public Health, Baltimore, Maryland, USA.
[4]
Department of Ophthalmology, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
[5]
Laboratory of Immunology, National Eye Institute, Bethesda, Maryland, USA.
[6]
Tampa Bay Uveitis Center, Tampa, Florida, USA.
[7]
Department of Ophthalmology, Oregon Health and Science University, Portland, Oregon, USA.
[8]
Department of Medicine, Oregon Health and Science University, Portland, Oregon, USA.
[9]
Portland Veteran's Affairs Medical Center, Portland, Oregon, USA.
[10]
Massachusetts Eye Research and Surgery Institution, Cambridge, Massachusetts, USA.
[11]
Department of Ophthalmology, Harvard Medical School, Boston, Massachusetts, USA.
[12]
Department of Ophthalmology, Massachusetts Eye and Ear, Boston, Massachusetts, USA.
[13]
MCM Eye Unit, MCM General Hospital and MyungSung Medical School, Addis Ababa, Ethiopia, USA.
[14]
DOI
10.1080/09273948.2020.1828493
PMID
33621148
发布时间
2022-04-30
换一批
换一批
